参考文献
(在框内滑动手指即可浏览)
[1] 高国璇, 辛灵, 刘倩, 等. St Gallen国际乳腺癌会议专家共识10年历程回顾 [J]. 中国实用外科杂志, 2014, 34(1): 70-72.
[2] 江泽飞, 李健斌. 乳腺癌诊疗指南和临床实践历程 [J]. 中华外科杂志, 2020, 58(2): 85-90.
[3] Burstein HJ, Curigliano G, Th rlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [J]. Ann Oncol, 2021.Doi: 10.1016/j.annonc.2021.06.023. [Online ahead of print].
[4] Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med, 2018, 379(22): 2108-2121.
[5] 郝晓鹏, 江泽飞. 三阴性乳腺癌新辅助治疗的机遇与挑战 [J]. 中华外科杂志, 2021, 59(2): 101-103.
[6] Von minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast Cancer [J]. N Engl J Med, 2019, 380(7): 617-628.
[7] 中国临床肿瘤学会乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会. 人表皮生长因子受体 2阳性乳腺癌临床诊疗专家共识 (2021版) [J]. 中华医学杂志, 2021, 101(17): 1226-1231.
[8] Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J]. Ann Oncol, 2013, 24(9): 2206-2223.
[9] 刘月平. 国际乳腺癌Ki-67工作组Ki-67评估更新的主要内容解读 [J]. 中华病理学杂志, 2021, 50(7): 704-709.
[10] Wang S, Li J, Jiang Z, et al. Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China [J]. Transl Breast Cancer Res, 2020, 1:1-11.
[11] Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study [J]. Lancet Oncol, 2021, 22(2): 212-222.
[12] Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE) [J]. J Clin Oncol, 2020, 38(34): 3987-3998.
[13] Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation [J]. N Engl J Med, 2017, 377(6): 523-533.
[14] Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer [J]. N Engl J Med, 2021, 384(25): 2394-2405.
[15] Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials [J].Lancet Oncol, 2013, 14(11): 1086-1094.
[16] Wang SL, Fang H, Hu C, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: A multicenter, randomized controlled trial from China [J]. J Clin Oncol, 2020, 38(31): 3604-3614.
[17] Cao L, Xu C, Cai G, et al. How does the interval between completion of adjuvant chemotherapy and initiation of radiotherapy impact clinical outcomes in operable breast cancer patients? [J]. Ann Surg Oncol, 2020, 28(4):1-14.
[18] 江泽飞, 许凤锐. 乳腺癌精准治疗:20年探索历程 [J]. 中国实用外科杂志, 2020, 40(1): 83-88.